Women’s Infertility - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Women's Infertility - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global women’s infertility therapeutics market. The report identifies the key trends shaping and driving the global women’s infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women’s infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global women’s infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015

Scope

The scope of the report includes:

• Annualized global women’s infertility therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Gonadotropin-Releasing hormone (GnRH) antagonists, AMP-activated protein kinase (AMPK) agonists, GnRH agonists, Recombinant human chorionic gonatropin, Follicle stimulating hormone, Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitor.
• Analysis of the current and future market competition in the global women’s infertility therapeutics market. The key future market players covered are Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA and Merck.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the women’s infertility market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global women’s infertility therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global women’s infertility therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the global women’s infertility therapeutics market landscape? Identify, understand and capitalize.

Contents

1.1 List of Tables
1.2 List of Figures

2 WOMEN’S INFERTILITY: INTRODUCTION

2.1 GlobalData Pipeline Report Guidance

3 WOMEN’S INFERTILITY: MARKET CHARACTERIZATION

3.1 Women’s Infertility Market Size
3.2 Women’s Infertility Therapeutics Market Forecast and CAGR
3.3 Drivers and Barriers for the Women’s Infertility Therapeutics Market
  3.3.1 Drivers for the Women’s Infertility therapeutics market
  3.3.2 Barriers for the Women’s Infertility therapeutics market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 WOMEN’S INFERTILITY: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Marketed Products for Women’s Infertility
  4.3.1 Clomid (clomiphene citrate)
  4.3.2 Ovidrel (Choriogonadotropin Alfa)
  4.3.3 GONAL-f (follitropin alfa)
  4.3.4 Cetrotide (cetrorelix acetate)
4.4 Comparison of Major Marketed Products for Women’s Infertility
4.5 Key Takeaway

5 WOMEN’S INFERTILITY: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Women’s Infertility Therapeutics – Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
  5.4.1 ELONVA (corifollitropin alfa injection)
5.5 Women’s Infertility Therapeutics – Clinical Pipeline by Mechanism of Action
5.6 Women’s Infertility Therapeutics – Pipeline by Clinical Phases of Development
  5.6.1 Women’s Infertility Therapeutics – Phase III Clinical Pipeline
  5.6.2 Women’s Infertility Therapeutics – Phase II Clinical Pipeline
  5.6.3 Women’s Infertility Therapeutics – Phase I Clinical Pipeline
  5.6.4 Women’s Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline
5.7 Key Takeaway

6 WOMEN’S INFERTILITY: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 WOMEN’S INFERTILITY: FUTURE PLAYERS IN THE WOMEN’S INFERTILITY MARKET

7.1 Introduction
7.2 Merck & Co.
  7.2.1 Company Overview
  7.2.2 Financial Performance
  7.2.3 Business Description
7.3 Dong-A Pharmaceuticals
  7.3.1 Company Overview
7.4 Ferring Pharmaceuticals
  7.4.1 Company Overview
7.5 PregLem SA
  7.5.1 Company Overview

8 WOMEN’S INFERTILITY: APPENDIX

8.1 Market Definitions
8.2 Scope of Pipeline Research
8.3 Abbreviations
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

LIST OF TABLES

Table 1: Women’s Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 2: Women’s Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017
Table 3: Comparison of Major Marketed Products for Women’s Infertility, 2010
Table 4: Women’s Infertility Therapeutics – Promising Drugs Under Clinical Development, 2010
Table 5: Women’s Infertility Therapeutics – Phase III Clinical Pipeline, 2010
Table 6: Women’s Infertility Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Women’s Infertility Therapeutics – Phase I Clinical Pipeline, 2010
Table 8: Women’s Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010
Table 9: Merck & Co. – Women’s Healthcare Pipeline Products, 2010
Table 10: Merck & Co. – Women’s Infertility Pipeline Portfolio, 2010
Table 11: Dong-A Pharmaceutical Co., Ltd. – Women’s Health Pipeline Portfolio, 2010
Table 12: Dong-A Pharmaceutical Co., Ltd. – Women’s Infertility Pipeline Portfolio, 2010
Table 13: Ferring Pharmaceuticals – Women’s Health Pipeline Portfolio, 2010
Table 14: Ferring Pharmaceuticals – Women’s Infertility Pipeline Portfolio, 2010
Table 15: PregLem SA – Women’s Health Pipeline Portfolio, 2010
Table 16: PregLem SA – Women’s Infertility Pipeline Portfolio, 2010

LIST OF FIGURES

Figure 1: Women’s Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009
Figure 2: Women’s Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017
Figure 3: Opportunity and Unmet Need in the Women’s Infertility Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for Women’s Infertility, 2010
Figure 5: Technology Trends Analytic Framework of Women’s Infertility Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of Women’s Infertility Pipeline – Description, 2010
Figure 7: Women’s Infertility Therapeutics– Clinical Pipeline by Mechanism Of Action, 2010
Figure 8: Women’s Infertility Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 9: Women’s Infertility – Implications for Future Market Competition, 2010
Figure 10: Women’s Infertility Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Merck & Co.
Dong-A Pharmaceuticals
Ferring Pharmaceuticals
PregLem SA Skip to top